New research reveals that patients who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end traditional lifestyle regimens.
Published data in a leading health publication points out that while obese people can lose about a fifth of their body weight while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation.
"People purchasing such treatments need to be aware of the potential of quick weight regain when the therapy ends," stated researcher Dr. Susan Jebb.
This pace of recovery suggests a return to starting mass in about one and a half years.
Comparing Approaches
The research, which examined dozens of studies involving over 9,000 of participants, compared the outcomes of the injectable medications with other pills.
Researchers point out that individuals who shed pounds through diet and exercise usually have a less rapid creep back—approximately 100 grams monthly—after stopping.
Understanding the Quick Rebound
Experts suggest the way of the jabs explains the accelerated regain.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of GLP-1 concentrations several times higher than normal could lead to the system to produce less of its endogenous hormone, and could diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication means hunger is unsuppressed, making binge eating far more likely."
A Lifelong Disease?
The NHS advise the jabs for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians contend that, given the likelihood of weight regain, the treatment is often long-term.
This opinion is echoed by pharmaceutical companies, who say that the results "highlight the persistent nature of obesity," similar to managing conditions like high blood pressure.
User Accounts
Users who have come off the jabs describe a powerful return of cravings.
"I experienced a trigger that goes on and I was suddenly starving," said one woman.
This challenge is compounded if patients have not adopted permanent dietary or behavioural changes during treatment.
Significant Interest
Recent estimates indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is more common among women compared to males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, researchers caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone cure and lasting health benefits relies on ongoing lifestyle changes.
